SOMEDAY YOU WILL REAP WHAT YOU SOW
India: The New Global Business Opportunity
Arun MairaThe Boston Consulting Group San Francisco
- 2 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
PRESSURES ON COMPANIES IN DEVELOPED COUNTRIES
Intense competition between firms in developed countries in their own developed country markets
Competition between firms for customers in developing countries
Emerging of new competitors from developing countries
Pressure on prices and margins
Need for innovations in products and business models
- 3 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
THREE OUT OF FOUR EXECUTIVES PLAN TO INCREASE INNOVATION SPENDING IN 2005
How will your company’s investments in innovation change this year?
5%
31%
64%
5%
21%
74%
0%
20%
40%
60%
80%
100%
Decrease No change Increase
2004 2005Percentage of respondents
Source: BCG 2005 ITC Survey
- 4 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
MOST EXECUTIVES ARE NOT SATISFIED WITH THE RETURN ON INNOVATION SPENDING
Are you satisfied with the financial return on your investments in innovation?
49% 52% 49% 48%
52%51%48%51%
0%
20%
40%
60%
80%
100%
World wide Asia Europe North America
Percentage of respondents
Source: BCG 2005 ITC Survey No
Yes
- 5 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
INCREASED COMPETITION IN DEVELOPED MARKETS REQUIRES INCREASING INVESTMENTS IN NEW CAR MODELS
Average life of new models (Europe)
14
4.6
4.5
5.1
5.1
6.0
6.7
7.2
7.2
8.0
7.5
7.2
7.4
9.7
9.1
9.2
8.07.5
0
2
4
6
8
10
12
14
16
80 82 84 86 88 90 92 94 96
Life (years)
Year of introduction
Increasing models and decreasing sales per model (US Market)
2050015000
0
10000
20000
30000
1980 1999
550
1050
0
500
1000
1500
1980 1999
Number of vehicle models(1)
Avg. total sales per model(2)
(1) Total number of models of cars and light trucks(2) Average total annual sales per modelSource: Automotive News
Case Study: Automobiles
- 6 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
INDIAN AUTOMOBILE INDUSTRY HAS DEVELOPED CAPABILITIES UP THE VALUE CHAIN
R&D/Product development
Component manufacture
Assembly
Low capital intensity, BEP <100k units/ annum (Global BEP is 150-200k units/ annum)
Total Manufacturing Cost 20- 30 % less than USA
Very high quality: 1 Japan Quality Medal and 5 Deming Prize Winners- largest number outside Japan
Exports growing 30% per annum; 80% to 'developed' countries
Global average development cost of new car > $600m
Tata Indica- $350 m
M & M Scorpio- $150 m
Case Study: Automobiles
- 7 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
COSTS OF MEDICINES AND HEALTHCARE SOARING IN DEVELOPED COUNTRIES
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2000 2001 2002
US
$ T
rill
ion
CAGR: 10.9%
Total USA Healthcare Spending
Source: EIU, Literature Review
US
$(‘
00
0s
)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2001 2002 2003 2004
UK Germany
CAGR UK: 9.2%CAGR Ger: 6.2%
Annual Household Expenditure on Healthcare
(EST)
Case Study: Healthcare and Pharma
- 8 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
R&D COSTS & PRODUCTIVITY OF US PHARMA PROBLEMATIC
Case Study: Healthcare and Pharma
- 9 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
LOW COST, HIGH QUALITY MEDICAL CAPABILITIES AVAILABLE IN INDIA
Not just cost advantage:
•The success rate in the 43,000 cardiac surgeries till 2002 was 98.5%
• India's success in 110 bone marrow transplants is 80%
Quality a Key Factor
Source: IBEF, Literature Review
8000
4000
600
30000
440050000
180000
400000
50000
850
0 20000 40000 60000 80000
Salary: Doctor
Salary: Nurse
Bone MarrowTransplant
Heart Surgery
Gall BladderTransplant
USA India
Healthcare Cost Differential
US$
Cost Saving
80%
91.2%
92.5%
98.8%
97.7%
Case Study: Healthcare and Pharma
- 10 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
COST EFFECTIVE AND GOOD QUALITY DRUG DEVELOPMENT AND MANUFACTURE
DRUGS IN USA
• Cost of development- hundreds of million dollars
• Amgen antibody- $10.00/ dose
• Cost of treatment- $20,000
INDIAN DRUG
• Time for development- 3 years
• Cost of development- $4 m!
• Cost of treatment- $50 !!
DEVELOPMENT(Example: Disease- Psoriasis)
5
7
9
22
25
60
61
0 20 40 60 80
Hungary
Israel
Taiwan
China
Spain
Italy
India
USFDA Approved Plants Outside USA
Case Study: Healthcare and Pharma
- 11 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
INDIA HAS A LARGE RESERVOIR OF HUMAN RESOURCESReaping What You Sow
Note: Potential surplus is calculated keeping the ratio of working population (age group 15 – 59) to total population constantSource: U.S. Bureau of the Census International Data Base; BCG Analysis
47M
India
0M
19M 7
M
3M
5M 3M Bangladesh
Pakistan
Iran
Brazil
MexicoPhilippines
5M
4M
Vietnam
2M
Turkey
5M
Indonesia
1MMalaysia
0M
Ireland
IsraelIraq
2M
4M
Egypt
-10M
China
-6 M
Russia
-1MCzechRepublic
-17M
U.S. -2M
U.K. -2MItaly
-3M
France
-9M Japan
Potential surplus population in working age group (2020)
- 12 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
SOMEDAY REAPING WHAT YOU SOW
• Vertical integration
• Small volumes, but growing
• Logistics & infrastructure problems
INDIA'S LEGACY
•Domain knowledge
•Software capabilities
•Remote delivery possible
INDIA'S STRENGTHS
MASSMANU-
FACTURING
REMOTELY PROVIDEDSERVICES
Small volume,
high variety, low cost
mfg
INDIA'S OPPORTUNITIES
- 13 -CII- Symposium on “India!-The New Global Business Opportunity - 11 Apr '05, San Francisco
INDIA EMERGING AS A "KNOWLEDGE SERVICES" HUB IN THE WORLD
Skilled people; Low costs; IT capabilities; English
Remotely delivered servicesImport of customers
to service in India
Transaction processing
Design and analysis
Research and development
Valueadded tourism
Leisure tourism
Information Tech
Pharma/Healthcare
Education Services
Auto/ engineering
Chemicals
Financial Services
Industry
Source: BCG Analysis